Loading clinical trials...
Loading clinical trials...
A Phase I, Open-Label Study of GSK1795091 Administered in Combination With Immunotherapies in Participants With Advanced Solid Tumors
Conditions
Interventions
GSK1795091
GSK3174998
+2 more
Locations
8
United States
GSK Investigational Site
Boston, Massachusetts, United States
GSK Investigational Site
St Louis, Missouri, United States
GSK Investigational Site
Dallas, Texas, United States
GSK Investigational Site
Houston, Texas, United States
GSK Investigational Site
Tacoma, Washington, United States
GSK Investigational Site
Toronto, Ontario, Canada
Start Date
March 26, 2018
Primary Completion Date
July 1, 2020
Completion Date
March 11, 2022
Last Updated
September 23, 2024
NCT03206060
NCT07542041
NCT07541924
NCT06608446
NCT00033137
NCT04389632
Lead Sponsor
GlaxoSmithKline
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions